Streetbeat News

Analyst Ratings

UE

Morgan Stanley analyst Richard Hill has reiterated an Underweight rating on Urban Edge Properties (NYSE:UE) and maintained a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:45 pm

CLX

Citigroup analyst Wendy Nicholson has reiterated a Neutral rating on Clorox (NYSE:CLX) and maintained a price target of $170.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:45 pm

TECK

Morgan Stanley analyst Carlos De Alba has reiterated an Overweight rating on Teck Resources (NYSE:TECK) and maintained a $53 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:45 pm

CHK

Citigroup analyst Paul Diamond has maintained a Neutral rating on Chesapeake Energy (NASDAQ:CHK) and raised the price target from $82 to $90.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:44 pm

SMPL

Morgan Stanley analyst Pamela Kaufman maintains an Equal-Weight rating on Simply Good Foods (NASDAQ:SMPL) and raises the price target from $34 to $37.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:44 pm

CHD

Citigroup analyst Filippo Falorni maintains a Neutral rating on Church & Dwight Co (NYSE:CHD) and raises the price target from $101 to $105.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:43 pm

RPRX

Morgan Stanley analyst Terence Flynn has reiterated an Overweight rating on Royalty Pharma (NASDAQ:RPRX) and maintained a $52 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:43 pm

CCK

Citigroup analyst Anthony Pettinari has maintained a 'Buy' rating on Crown Holdings (NYSE:CCK) but lowered the price target from $104 to $102.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:43 pm

CBOE

Citigroup analyst Christopher Allen has reiterated a Neutral rating on Cboe Global Markets (BATS:CBOE) and maintained a $130 price target.

Portfolio Pulse from richadhand@benzinga.com

July 11, 2023 | 1:42 pm

RVNC

Morgan Stanley analyst Terence Flynn has reiterated an Equal-Weight rating on Revance Therapeutics (NASDAQ:RVNC) and maintained a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 1:41 pm